GlassScriptPhysician profile
Sarah M Hall
NPI 1659529279
$51,537.46
in general payments reported to CMS, 2019-2025
23 companies · $8,716 in 2025
The $8,716 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $397 · 2021: $15K · 2022: $19K · 2023: $7,575 · 2024: $288 · 2025: $8,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,759.26 |
| Food and Beverage | $819.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $44,473.06 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $5,545.87 | 2019-2021 | |
| Amarin Pharma, INC. | $380.30 | 2020-2021 | |
| Abbvie INC. | $156.18 | 2019-2024 | |
| Insulet Corporation | $147.27 | 2024 | Omnipod |
| Pfizer INC. | $123.19 | 2019-2025 | |
| Exact Sciences Corporation | $101.72 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $97.20 | 2019-2022 | |
| Novo Nordisk INC | $75.53 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $55.96 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $53.86 | 2019-2022 | |
| Lilly USA, LLC | $50.07 | 2020-2023 | Trulicity, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $44.27 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $40.50 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $34.22 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.53 | 2022-2023 | Jardiance |
| Hologic Sales and Service, LLC | $23.24 | 2024 | Aptima, Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.42 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $20.05 | 2025 | Inspire |
| Dexcom, INC. | $16.92 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.20 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.37 | 2020 | |
| Therapeuticsmd, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.